Don't invest unless you're prepared to lose all the money you invest. This is a high risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more
|
|
|
|
|
|
COMING SOON
SymPhysis Medical
|
|
|
SymPhysis Medical is a medtech company tackling fluid build-up and breathlessness in late-stage cancer. Its releaze® device aims to improve patient independence, comfort, and control, addressing a major unmet need in a growing market. With over $12M+ secured from leading life science investors, Enterprise Ireland and clinical partners, they are launching an equity raise on Republic Europe.
Sign up for priority access and explore this campaign opportunity below 👇.
|
|
🏆 OPPORTUNITY
With limited innovation in this space for nearly 30 years, the releaze System was designed with today’s patients and families in mind.
-
Growing Global Demand: The global pleural effusion market is valued at approximately $5B and is expected to grow at a rate of up to 7%.
-
Defensible Technology: The releaze System has strong IP barriers and clear differentiation in the drainage market.
-
Strong Endorsements: Endorsed by the EIC, SymPhysis has secured over $12M+ and is supported by leading life science investors, Enterprise Ireland, and clinical partners.
|
|
⚡ INNOVATION AND GROWTH
The releaze System delivers a unique and intuitive patient experience by aligning with the latest trends in healthcare delivery and commercial scale:
-
Shift to Care at Home: The system supports modern preferences for minimally invasive procedures, allowing patients to safely manage their care outside of a hospital setting.
-
Healthcare System Savings: By shifting care to the home, the device directly improves the economics of building a scalable business while delivering significant national healthcare system savings.
-
Imminent Commercialisation: Backed by an experienced leadership team and board to drive commercial success, SymPhysis is currently finalising efforts towards FDA submission and commercialisation within the next 12 months.
|
|
|
|
|
Investing involves risks, including the risk of partial or entire loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Your investment is not covered by a deposit guarantee scheme or by an investor compensation and scheme. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future. Republic Europe does not make investment recommendations to you and any investment decision should be made on the basis of the full campaign. No communications from Republic Europe, through email or any other medium, should be construed as an investment recommendation.
|
|
|
This financial promotion and marketing communication has been approved by Seedrs Limited, authorised and regulated by the Financial Conduct Authority and Seedrs Europe Limited regulated by the Central Bank of Ireland both trading as Republic Europe, on 8 June 2026.
© Seedrs Limited 2026. All rights reserved. Republic Europe is a registered European Community trademark (No. 008771537), registered United Kingdom trademark (No. UK00908771537) and registered United States service mark (No. 85423072). Seedrs Europe Limited is a private company limited by shares registered in Ireland (No. 699574), with registered office at 42, Pearse Street, Dublin 2, D02 YX88, Ireland. Seedrs Limited is a limited company registered in England and Wales (No. 06848016), with registered office at Cubo Soho, Ilona Rose House, Manette Street, London W1D 4AL, United Kingdom, VAT No. GB 208 3065 32.
europe.republic.com is a website owned and operated by Seedrs Europe Limited and/or Seedrs Limited (each trading as Republic Europe).
This message and any attachments are confidential, and may be protected by legal privilege. Nothing in this message shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind, and nothing in this email constitutes such advice. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe or its affiliates, you should consult a professional adviser.
Don't want to receive any Featured Campaign Updates? Unsubscribe here. To manage your Republic Europe marketing communications please visit your preferences centre.
|
|
|
|
